• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Biology: Cellares Raises $257M to Industrialize Cell Therapy

by Jasmine Pennic 01/28/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Biology: Cellares Raises $257M to Industrialize Cell Therapy

What You Should Know

  • The News: Cellares has raised $257M in Series D financing, bringing its total capital to $612 million. The round was co-led by BlackRock and Eclipse.
  • The Tech: Cellares is building the world’s first IDMO (Integrated Development and Manufacturing Organization). Its Cell Shuttle™ and Cell Q™ platforms fully automate the manufacturing and quality control of cell therapies, replacing “artisanal” manual processes.
  • The Scale: The company claims its automated “Smart Factories” can deliver 10x higher throughput and lower per-patient costs compared to traditional CDMOs. Commercial-scale manufacturing is slated to begin in 2027.

Why BlackRock and Bristol Myers Squibb Are Betting Robots Can Fix the Cell Therapy Bottleneck

Cellare, the first Integrated Development and Manufacturing Organization (IDMO) announced a massive $257M Series D financing co-led by investment BlackRock and Eclipse, the round brings Cellares’ total funding to over $612M. The capital will fuel the construction of automated “Smart Factories” in the U.S., Europe, and Japan, aiming to turn cell therapy from a boutique craft into a global industry.

“The barrier to curing more patients is no longer scientific – it is industrial,” said Fabian Gerlinghaus, CEO of Cellares.

The Rise of the IDMO

Cellares is pioneering a new category: the IDMO (Integrated Development and Manufacturing Organization). Unlike traditional Contract Development and Manufacturing Organizations (CDMOs) that rely on cleanrooms filled with human operators, Cellares relies on robotics.

The company’s model is built on two proprietary platforms:

  1. Cell Shuttle™: An end-to-end, closed-system factory-in-a-box that automates the entire production line.
  2. Cell Q™: An automated platform for in-process and release testing, solving the quality control bottleneck.

The efficiency gains are staggering. Cellares claims these systems provide 10-fold higher throughput and significantly lower costs. To match the output of one Cellares facility, a conventional CDMO would need to build 10 facilities and hire thousands of employees. Cellares needs only hundreds.

Recent Traction/Milestones

The “high-tech backbone” Cellares is building has already attracted heavyweights. The company previously entered a $380M agreement with Bristol Myers Squibb, reserving capacity for commercial-scale CAR-T manufacturing.

Furthermore, the Cell Shuttle has received the FDA’s Advanced Manufacturing Technology (AMT) designation. This is a critical regulatory fast-track that allows for expedited review of drugs manufactured on the platform—a major incentive for biotech partners to switch from manual to automated processes.

The Roadmap to 2027

With this fresh capital, Cellares is moving from development to deployment. The company expects to support clinical manufacturing by the first half of 2026, with full commercial-scale manufacturing coming online in 2027.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |